Tirbanibulin, sold under the brand name Klisyri, is a medication used for the treatment of actinic keratosis (AK) on the face or scalp.

[8] The drug in various ways mimics the mechanisms of chemotherapy[12] by suspending the protooncogenic Src tyrosine kinase signaling pathway.

Notably, it promotes G2/M arrest during cell cycle, upregulates p53, and triggers apoptosis via caspase-3 stimulation and poly (ADP-ribose) polymerase cleavage.

[5] Participants received once daily treatment with either tirbanibulin or inactive control ointment for 5 consecutive days to the single predetermined area where they had actinic keratosis.

[5] The benefit of tirbanibulin in comparison to control was assessed after 57 days by comparing the percentage of participants who did not have any actinic keratosis on the treatment area (100% clearance).